Item 7.01 Regulation FD.

On January 10, 2020, LogicBio Therapeutics, Inc. (the "Company") announced the submission of an investigational new drug application to the U.S. Food and Drug Administration for LB-001 in methylmalonic acidemia and provided other business updates. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

On January 10, 2020, the Company also announced a research collaboration with Takeda Pharmaceutical Company Limited to further develop LB-301 in Crigler-Najjar syndrome. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.2 and is incorporated herein by reference.

Except as shall be expressly set forth by specific reference, the information contained or incorporated by reference in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit
  No.       Description

99.1          Press Release issued by LogicBio Therapeutics, Inc. on January 10,
            2020.

99.2          Press Release issued by LogicBio Therapeutics, Inc. on January 10,
            2020.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses